Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-25-107604·NovoCure Ltd
Schedule 13G ownership disclosure
NOVOCURE LTD ORD SHS
Ordinary Shares, no par value per share · CUSIP: G6674U108
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Soleus Capital Master Fund, L.P.
Shares: 9,644,872.00 · Class: 8.6%
- Soleus Capital, LLC
Shares: 9,644,872.00 · Class: 8.6%
- Soleus Capital Group, LLC
Shares: 9,644,872.00 · Class: 8.6%
- Soleus Capital Management, L.P.
Shares: 9,644,872.00 · Class: 8.6%
- Soleus GP, LLC
Shares: 9,644,872.00 · Class: 8.6%
- Guy Levy
Shares: 9,644,872.00 · Class: 8.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-107604
- Form type
- SCHEDULE 13G/A
- Filer
- NovoCure Ltd
- CIK
- CIK 1645113
- Filed
- Nov 07, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership